BioPharma« Terug naar discussie overzicht

1. [verwijderd] 7 november 2006 20:22

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com, Inc. Reports ''Significant and Unique'' Bird Flu Virus Testing by the Company
   Friday November 3, 9:40 am ET
   Testing is Being Conducted on the Actual H5N1 Strain of the Bird Flu Virus
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today provided additional information regarding yesterday's announcement to shareholders and the investment community about the testing of Citroxin against the Bird Flu virus at Innova Biotechnology Co., Ltd. (http://www.innovabiotechnology.com) in Thailand. This testing is especially significant because it is being conducted on the actual H5N1 strain of the Bird Flu virus, not the surrogate H9N2 strain that most domestic laboratories are currently using in their Bird Flu testing. Citroxin can be sprayed on bird cages and hen houses without it being harmful to animals or humans in surrounding areas if ingested.
   
   ADVERTISEMENT
   The Company has taken the time to locate a facility that has the actual H5N1 Bird Flu virus that has killed millions of birds in Asia and the actual strain that has led to human deaths. The significance of eFoodSafety's groundwork testing to date will allow the Company to report results taken against the exact H5N1 virus, the viral strain that has killed millions of birds and some humans over the past several years.
   
   The Company is also closely monitoring the H5N1 virus because indications are that a mutated strain of Bird Flu virus, a "Fujian-like strain," has emerged in response to vaccination programs designed to halt the disease in farm flocks. Indications are that this strain has emerged abroad, but not domestically yet.
   
   Patricia Gruden, President and CEO of eFoodSafety.com, Inc., stated, "Experts continue to renew their warnings of a Bird Flu pandemic and the World Health Organization continues to express its fear that a Bird Flu pandemic could kill millions in a worst case scenario. For that reason, testing with Citroxin is significant and unique in that we are at the forefront of testing on the exact and specific H5N1 strain of the Bird Flu virus that has been found to be the cause of human deaths."
   
   Mrs. Gruden further observed, "Having established clearly defined testing protocol guidelines on testing of the actual H5N1 Bird Flu virus enables eFoodSafety to be at the forefront of testing, with the next level of testing on live subjects already in place. The Company's Citroxin formulation represents one of the products we are developing as we continue to work toward our ultimate goal of becoming a provider of global healthcare technologies."
   
   About eFoodSafety.com, Inc.
   
   eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has recently entered into a joint venture agreement with CK41 Direct, Inc. to launch an anti-acne skin care system, with a branded name and celebrity spokesperson to be announced in the near future.
   
   Please visit the Company's website at: www.efoodsafety.com.
2. [verwijderd] 7 november 2006 20:23

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com, Inc. Announces Groundbreaking Laboratory Test Results Against Tuberculosis with its Trimycin Product
   Tuesday November 7, 9:50 am ET
   Test results demonstrated killing the Tuberculosis organism while remaining non-toxic to normal cells
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), dedicated to improving health conditions around the world through innovative products and technologies, today announced that the Company received positive laboratory test results on the eradication of Tuberculosis organism (Mycobacterium Tuberculosis) with the use of its patent-pending product Trimycin. The testing was conducted by the National Center for Genetic Engineering and Biotechnology (BIOTEC), a branch of the National Science and Technology Development Agency (NSTDA) located in the greater Bangkok metropolitan area of Thailand.
   
   ADVERTISEMENT
   Testing consisted of using live tissue samples inoculated with Mycobacterium Tuberculosis exposed to various concentrations of Trimycin. The test results demonstrated that Trimycin killed the Tuberculosis organism while remaining non-toxic to normal cells. The ability of Trimycin to eradicate the Tuberculosis organisms within the cells without affecting the normal cells is of major impact in the treatment of Tuberculosis (TB).
   
   According to Global Health Reporting.org, more than 8 million people develop active TB annually, and approximately two million die from the disease each year. Of the estimated 8.9 million cases worldwide, over 700,000 were also HIV-positive. In 2004, 1.7 million people died of TB and fifteen percent (15%) of those who died were also infected with HIV. Global access to TB treatment remains low and very expensive. The Company feels that this is where Trimycin could have a major impact on the treatment of TB.
   
   "We are now able to progress to live subjects to continue our testing on this groundbreaking discovery of Trimycin's effect on TB. We believe eFoodSafety is well positioned in the treatment of this deadly disease and we hope to make a major contribution to the world in the treatment of deadly infectious diseases," stated Mr. Robert Bowker, President and CEO of Knock-Out Technologies, Ltd., a wholly-owned subsidiary of eFoodSafety.com, Inc., and formulator of the patent-pending Trimycin product.
3. [verwijderd] 11 januari 2007 12:06

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com, Inc. Provides Update to Shareholders on Company's MedElite and Direct Marketing Divisions
   Thursday November 9, 10:05 am ET
   Company's Flagship Anti-Acne Product Set to Launch Early 2007 to a Multi-Million Dollar Market Opportunity
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF - News), dedicated to improving health conditions around the world through innovative products and technologies, today announced an update to its shareholders and the investment community on the Company's MedElite and Direct Marketing divisions.
   
   ADVERTISEMENT
   The MedElite subsidiary has acquired all of the trademarks, patents, and manufacturing and distribution rights for the Talsyn(TM)-CI/bid scar cream and seven other products in the Talsyn(TM) line. The Company intends to create a Talsyn(TM) Professional line to be sold to the professional market concurrently with the Talsyn(TM)-CI/bid scar cream. MedX, the U.S. Distributor of Talsyn(TM)-CI/bid scar cream, has been consistently generating increasing month over month sales. Two new Talsyn(TM) products are currently scheduled to be launched by year end.
   
   Cinnergen, the Company's diabetes product, continues to show consistent sales growth. Retail sales continue to grow as we continue working on developing the brand in the marketplace. The Company anticipates national retail chains to begin retailing the product in the first quarter of 2007.
   
   The Company intends to announce shortly the name of its new anti-acne product along with the celebrity host and guest stars who will be endorsing the product. Testimonials and production of the direct response campaign are underway for an early 2007 product launch.
   
   Patricia Gruden, President and CEO of eFoodSafety.com, Inc., stated, "We are excited and optimistic to be on the verge of launching our anti-acne solution. Our joint venture partner CK41 Direct has previously projected that our products' potential market opportunity is significant, potentially amounting to millions in annual sales. With a product that we believe to be superior to that of the competition, we are eagerly looking forward to entering this immense and potentially very profitable market."
   
   Gruden further commented, "It's clearly an exciting time at eFoodSafety.com as evidenced by the string of recently announced positive developments. Despite being pleased with our notable progress, we remain diligently focused on the continued execution of our business plan with a common goal of building long term shareholder value."
   
   About eFoodSafety.com, Inc.
4. [verwijderd] 11 januari 2007 12:07

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com, Inc. Secures Trademarked Name 'PurEffect(TM)' for New Anti-Acne Product
   Monday November 13, 9:45 am ET
   CK41 Direct, Inc. Reconfirms Initial Sales Projections Could Reach $200 Million
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF - News), dedicated to improving health conditions around the world through innovative products and technologies, and its joint-venture partner CK41 Direct, Inc. (http://www.ck41.com/), a firm engaged in the marketing, production, and distribution of infomercials, today announced that the trademarked name "PurEffect(TM)" has been secured for the Company's previously announced anti-acne skin care system.
   
   ADVERTISEMENT
   The trademarked name was purchased from Christine Valmy, Inc.
   
   According to market research, 85% of the U.S. population between the ages of 12-25 years develops some form of acne and a total of 17 million Americans are currently plagued with acne. Skin problems are exceedingly common, resulting in Americans spending close to $4 billion each year for the treatment of psoriasis, eczema and acne.
   
   Christine McDonald, CEO of CK41 Direct, Inc., stated, "We are excited to have commenced this exciting project with our partner eFoodSafety. Securing a recognizable trade name such as PurEffect(TM) is the first step in our roll-out and branding strategy for the product's forthcoming direct response campaign. Testimonials have been secured and production of the direct response campaign is currently underway, with an anticipated first quarter 2007 launch date. We are eager to introduce this product to market as our market studies further confirm that sales of PurEffect(TM) could reach our original projections of $200 million domestically. We expect to announce our celebrity host and guest stars shortly."
   
   About eFoodSafety.com, Inc.
5. [verwijderd] 11 januari 2007 12:08

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com, Inc. Commences Testing of Influenza A Virus in Conjunction with Bird Flu Virus Testing
   Wednesday November 15, 10:19 am ET
   Bird Flu Virus Bears Resemblance to Influenza Pandemic That Struck after WWI Killing 50 Million People
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that the Company has commenced the testing of its Citroxin product on the Influenza A virus in conjunction with its testing of Citroxin against the Bird Flu virus.
   
   ADVERTISEMENT
   The testing is being conducted at Innova Biotechnology Co., Ltd. (http://www.innovabiotechnology.com), one of Thailand's largest private biotechnology companies specializing in advanced research, development and manufacturing of rapid immunodiagnostic test devices for health care applications. The company is a joint-venture enterprise in Thailand between leading private business and scientists and the National Science and Technology Development Agency (NSTDA), and is supported by the National Center for Genetic Engineering and Biotechnology (BIOTEC) and the National Innovation Agency.
   
   The only recognized treatment currently being used in an attempt to combat the Bird Flu virus is a product designed to treat the Influenza A virus. The treatment's efficacy is questionable, and it is for this reason that eFoodSafety believes testing of its Citroxin product on the Influenza A virus could easily transpose test results to the Bird Flu virus and allow for a more rapid acceptance of product domestically.
   
   The United Nations Coordinator on the Bird Flu, David Nabarro, has stated that, "The Bird Flu virus will likely remain a significant global threat for animals and humans for the next decade." He further stated, "The risk of a mutation to cause a pandemic is still very much there."
   
   The Company periodically updates it shareholders on newsworthy Bird Flu events in an effort to clearly and precisely illustrate the importance of this issue as well as the potential economic impact a solution could have on the Company and its shareholders.
   
   About eFoodSafety.com, Inc.
6. [verwijderd] 11 januari 2007 12:08

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com, Inc. (EFSF) SqueezeTrigger Price is $0.32 -- Approximately 17.2 Million Shares Shorted Since January 2005 According to Buyins.net Research Report
   Monday November 27, 9:30 am ET
   The First of Several Short Squeezes is Expected to Begin When Shares of EFSF Close above $0.20
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF - News) announced today that BUYINS.NET, www.buyins.net, is reiterating coverage of eFoodSafety.com, Inc. after releasing the latest short sale data to November 2006. From January 2005 to November 2006 approximately 223 million total aggregate shares of EFSF have traded for a total dollar value of nearly $71.9 million. The total aggregate number of shares shorted in this time period is approximately 17.2 million shares. The Total Short Interest on October 10th was 10,770 and only accounts for shares that were shorted but not yet covered on October 10th. The EFSF SqueezeTrigger price of $0.32 is the volume weighted average short price of all short selling in EFSF. The first of several short squeezes is expected to begin when shares of EFSF close above $0.20, where nearly 1.5 million shares have been shorted in the $0.18 to $0.20 range. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit www.buyins.net.
   
   Month Total Vol. Short Vol. Avg. Price Short $ Value
   -------------------- ------------ ----------- ---------- -------------
   
   January '05 12,389,046 953,957 $0.45 $432,905
   February 5,361,430 412,830 $0.43 $176,485
   March 6,363,580 489,996 $0.37 $180,710
   April 5,622,011 432,895 $0.39 $168,699
   May 3,741,859 288,123 $0.34 $97,616
   June 4,417,015 340,110 $0.28 $95,673
   July 3,624,760 279,107 $0.27 $74,242
   August 5,172,127 398,254 $0.23 $89,607
   September 9,968,698 767,590 $0.27 $210,089
   October 4,260,734 328,077 $0.31 $100,063
   November 2,478,910 190,876 $0.27 $50,792
   December 7,478,887 575,874 $0.25 $140,916
   January '06 10,572,850 814,109 $0.28 $229,009
   February 5,912,471 455,260 $0.30 $137,033
   March 55,640,312 4,284,304 $0.37 $1,601,473
   April 25,395,344 1,955,441 $0.37 $714,714
   May 14,809,001 1,140,293 $0.30 $346,079
   June 5,242,800 403,696 $0.28 $113,560
   July 9,022,078 694,700 $0.27 $186,666
   August 6,149,582 473,518 $0.23 $108,341
   September 7,631,441 587,621 $0.20 $117,642
   October 4,768,648 367,186 $0.19 $68,407
   November 6,940,192 534,395 $0.18 $95,550
   
   Total: 222,963,776 17,168,211 $0.32 $5,536,272
   
   +short volume is approximated using a proprietary algorithm.
   ++average short price is calculated using a volume weighted average
   short price.
   +++short volume is the total short trade volume and does not account
   for covers.
   
   About eFoodSafety.com, Inc.
7. [verwijderd] 11 januari 2007 12:09

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com, Inc. Announces Major Breakthrough with Positive Laboratory Results on Deadly Malaria with its Auromoxin Product
   Tuesday November 28, 10:00 am ET
   Testing Results in Level of Complete Eradication with no Cytotoxcity to Normal Surrounding Cells
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB: EFSF - News), dedicated to improving health conditions around the world through innovative products and technologies, today announced that the Company has completed laboratory testing of Auromoxin on Malaria. Auromoxin is a patent-pending formula designed to eradicate multiple hazardous organisms without adversely affecting the host (animal, human being). The breakthrough technology was tested at the National Center for Genetic Engineering and Biotechnology (BIOTEC), a branch of the National Science and Technology Development Agency (NSTDA), located in the greater Bangkok metropolitan area of Thailand.
   
   ADVERTISEMENT
   Testing consisted of using live tissue samples inoculated with Malaria (Plasmodium Falciparum) exposed to different concentrations of Auromoxin. Testing resulted in a level of complete eradication of Malaria with no cytotoxcity to normal surrounding cells. This positive result enables the testing to proceed to the next step of testing on live animals. "This is a landmark accomplishment in the fight against Malaria, this worldwide lethal infectious disease," stated Robert Bowker, President and CEO of Knock-Out Technologies, Ltd., a wholly-owned subsidiary of eFoodSafety.com, Inc., and the formulator of Auromoxin.
   
   According to Global Health Reporting.org, at least 200 million acute cases of Malaria occur worldwide each year, resulting in more than one million deaths annually. More than 80% occur in Africa, mostly among children under the age of five. Recent estimates are even higher with 515 million cases annually. Overall, Malaria costs Africa alone more than $12 billion annually. Although, Africa has the most cases worldwide, one-third of clinical Malaria cases occur in Asia and 3% in the Americas.
   
   eFoodSafety.com, Inc. President and CEO Patricia Ross Gruden commented, "Today clearly marks an important day for eFoodSafety.com, Inc. and the fight against Malaria. The Company is extremely grateful to Mr. Bowker for his important work leading to this crucial discovery. With recent estimates of annual Malaria cases ranging as high as 515 million, a solution like Auromoxin could offer a remarkable opportunity to benefit the millions afflicted annually with Malaria. As for market share, Auromoxin has a market potential well into the millions."
   
   About eFoodSafety.com, Inc.
   
   eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The company is also is a distributor for Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has recently entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
   
   Please visit the Company's website at: www.efoodsafety.com.
8. [verwijderd] 11 januari 2007 12:09

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com, Inc. Purchases All Rights, Title and Interest to Cinnergen
   Thursday November 30, 10:04 am ET
   Existing Retail Distribution Network Expected to Create Reoccurring Revenue
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that the Company has purchased from NutraLab, Inc. all rights, title, and interest to Cinnergen(TM), a once-a-day formula made from 15 whole foods that contain no fats, carbohydrates, sugar, or calories that is designed to regulate blood sugar.
   
   ADVERTISEMENT
   The timing of this strategic purchase by the Company was lead by its Board of Directors and management as the product is now well entrenched with several national retail chains, such as GNC, Vitamin Shoppe, and various other independent retailers. Indications are that other major national retailers may be featuring Cinnergen(TM) in the very near future.
   
   Patricia Gruden, President and CEO of eFoodSafety.com, Inc. stated, "We purchased the product after quantifiable sales patterns were established and consistent and increasing sell-through of the product was demonstrated. It is our goal that through this purchase we will create reoccurring and increasing revenue. In addition, we intend to leverage and build on our existing retail pipeline as the Company has various products it intends to bring to market in the near future."
   
   Gruden further commented, "We remain focused on executing our business plan with the goal of enhancing shareholder value. That other pharmaceutical companies are devoting considerable resources to the diabetes market tells us that our purchasing a proven product with existing distribution channels in that market has potential exponential growth."
   
   About eFoodSafety.com, Inc.
   
   eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The company is also owner of Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
   
   Please visit the Company's website at: www.efoodsafety.com.
   
   Safe Harbor Forward-Looking Statements
9. [verwijderd] 11 januari 2007 12:09

   auteur info

   •    [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   •    Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   eFoodSafety.com, Inc. Announces Cinnergen is Now Available at Innovative Health Care Centers, Kerr Drug
   Thursday December 7, 9:45 am ET
   
   SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that the Company's Cinnergen(TM) product, a once-a-day formula made from 15 whole foods that contain no fats, carbohydrates, sugar, or calories that is designed to regulate blood sugar, is available at Kerr Drug stores and Kerr Health Care Centers in North and South Carolina (http://www.kerrdrug.com).
   
   ADVERTISEMENT
   Kerr Drug has taken the vision of community pharmacy farther than any other drug chain by placing its future on its unique ability to provide patients, the medical community, and health plan sponsors access to the most comprehensive and convenient health and wellness offering in the industry. Kerr is currently providing services in many of its stores that far exceed the traditional drug store mix. Kerr's vision of retail community pharmacy is on the cutting edge of everything innovative about diagnostic, disease state, and drug therapy management.
   
   With its vast, visionary experience in clinical pharmacy, Kerr has transformed about 10% of its stores into full Kerr Health Care Centers. Complementing the traditional dispensing pharmacy is a large, adjacent center with all of the affordable and easily accessed health screenings, such as diabetes, cholesterol, osteoporosis, thyroid disease, PSA, peripheral artery disease, skin damage, plus programs for smoking cessation, weight loss, asthma management, and more. Offering more than just diagnostic tests, however, the Kerr Health Care Centers have on staff a dedicated health care specialist to assist with a full Durable Medical Equipment selection of walkers, canes, motorized lift chairs, bath-safety-mobility products and home health. They are trained to fit therapeutic compression hosiery and diabetic shoes, file Medicare & Medicaid, and assist the large senior population who often has many health care issues. In a world where alternative avenues to the most efficient and convenient health care are increasingly critical, Kerr Drug has set a new standard of innovation and excellence for its customers.
   
   Patricia Gruden, President and CEO of eFoodSafety.com, Inc., stated, "The mission of Kerr Drug is to be the most comprehensive provider of pharmacy and related health care services, while continuing to be the most reliable provider of health-related and convenience items. eFoodSafety has much in common with this philosophy as we continue to develop superior products with mass appeal for a broad range of illnesses and indications."
   
   About eFoodSafety.com, Inc.
   
   eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax, and a germicidal product, Citroxin (formerly named Big Six Plus) -- EPA Reg. No. 82723-1, that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The company is also owner of Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
   
   Please visit the Company's website at: www.efoodsafety.com.
10. [verwijderd] 11 januari 2007 12:10

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    eFoodSafety.com, Inc. Returns Over Thirty Million Common Shares to Treasury
    Tuesday December 12, 9:00 am ET
    Reduces Company's Outstanding Share Count by Over 20%
    
    SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that over thirty million (30,000,000) common shares have been returned to the Company's treasury, reducing eFoodSafety.com, Inc.'s issued and outstanding shares by over twenty percent (20%).
    
    ADVERTISEMENT
    On September 29, 2006 in the Superior Court of the State of California, County of Riverside, a judgment was entered in favor of eFoodSafety.com, Inc. for the principal sum of $9.2 Million against its former Chairman and CEO. As partial settlement, the shares issued to him in 2003 were returned to the Company after a garnishment proceeding.
    
    Patricia Gruden, President and CEO of eFoodSafety.com, Inc. stated, "The Company has spent over two years litigating this matter. The ruling handed down by the Riverside Superior Court is final and all appeal attempts were denied. The Company has proceeded through the judicial system to attain a judgment and garnishment of these shares. While this process took longer than we anticipated, we were diligent to ensure it was resolved completely in order to secure a ruling that was both final and binding."
    
    Gruden further added, "We are pleased to have this issue now behind us. The return of these shares and the cancellation of an additional five million shares reduce our outstanding shares by just over 20% and, we expect, the permanent removal of these shares from the public float will serve to dramatically enhance future earnings leverage. Further, we will continue to work hard and as long as necessary to preserve and build value on behalf of our shareholders."
    
    About eFoodSafety.com, Inc.
    
    eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The company is also owner of Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
    
    Please visit the Company's website at: www.efoodsafety.com.
    
    Safe Harbor Forward-Looking Statements
11. [verwijderd] 11 januari 2007 12:10

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Form 8-K for EFOODSAFETY COM INC
    
    13-Dec-2006
    
    Other Events
    
    Item 8.01. Other Events
    
    As previously announced, the Company had filed a complaint in the Superior Court of Riverside County, California on November 5, 2004 against Clarence W. Karney, a founder and former officer and director of the Company, and others, alleging breach of fiduciary duty, conversion and fraud. eFoodSafety.com, Inc. v. Karney, et al. (Case No. INC 046894). The Company alleged that Karney misappropriated funds from the Company and attempted to cause the Company to enter into invalid contracts with close personal friends without proper authorization. A default was entered against Karney and then a default judgment for $9,284,910.30 was entered against him on September 29, 2006.
    
    The Company then filed a writ of garnishment in the Judicial District Court, Collin County, Texas, against Signature Stock Transfer, Inc., the Company's transfer agent that held certificates evidencing 25,192,500 shares of the Company's common stock registered in Karney's name, to execute upon such shares to satisfy $4,559,842.50 of the judgment against Karney. On November 15, 2006, the court entered an order directing the transfer agent to deliver the shares to the Company. Appeals were unsuccessful and the judgment is final.
    
    The Company then cancelled the 25,192,500 shares and an additional 5,000,000 shares, for a total of 30,192,500 shares, reducing the number of the Company's issued and outstanding shares to 150,921,980.
12. [verwijderd] 11 januari 2007 12:11

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Form 10QSB for EFOODSAFETY COM INC
    
    15-Dec-2006
    
    Quarterly Report
    
    ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION.
    
    SPECIAL NOTE REGARDING FORWARD-LOOKING INFORMATION AND RISK FACTORS
    
    Certain statements in this annual report constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements deal with our current plans, objectives, projections, expectations, assumptions, strategies, and future events. Words such as "may," "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates," "will," "should," "could," and variations of such words and similar expressions are intended to identify such forward-looking statements. Similarly, statements that describe our plans, our strengths and weaknesses and other information that is not historical information also are forward-looking statements.
    
    Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements, expressed or implied by such forward-looking statements. Such factors include, among others, the following: general economic and business conditions, which will, among other thing, impact the ability of the Company to implement its business strategy, and changes in, or failure to comply with, governmental regulations affecting health and nutricutical products.
    
    In addition to the other information contained in this report, the following risk factors, among others, that make investment in shares of the Company's common stock speculative and risky should be carefully considered.
    
    POOR FINANCIAL POSITION. For each of the fiscal years ended April 30, 2004, 2005 and 2006, we had net losses of $1,735,965, $4,276,894 and $9,385,323, respectively. At April 30, 2006, the deficit accumulated since inception on October 16, 2000 was $16,043,832. As a result of our poor financial position and recurring losses from operations, we require considerable additional financing to continue as a going- concern. The continuing financial support of directors, officers and shareholders to satisfy our liabilities and commitments as our operations are commencing to generate revenues is essential to the continuation of the Company and there can be no assurance that such financial support will be available in the future.
    
    DEPENDENCE ON KEY PERSONNEL. The success of the Company is largely dependent upon the continued contributions of its key management personnel, particularly Patricia Gruden and Robert Bowker. The success of the Company also depends upon its ability to attract and retain additional qualified personnel. The process of locating personnel with the combination of skills and attributes required to implement our strategies is very competitive and there can be no assurance that we will be successful in attracting and retaining such personnel, particularly in view of our poor financial position. The loss of the services of our key management personnel or the inability to attract and retain additional qualified personnel could limit or disrupt our future business operations.
    
    NO DIVIDENDS EXPECTED. We have not paid any cash or other dividends on our common shares since inception and we do not expect to pay any dividends in the future. We expect to use any earnings in our operations.
    
    INTENSE COMPETITION IN THE HEALTH INDUSTRIES. There is intense competition among providers, both individuals and entities, of various technologies to improve health conditions. Many of these competitors have substantially greater financial and marketing resources than the Company, stronger name recognition, brand loyalty and long-standing relationships with our target customers. Our future success is dependent upon our ability to compete and our failure to do so could adversely affect our business, financial condition and results
    
    of operation.
    
    LIMITED OR SPORADIC MARKET QUOTATIONS; POSSIBLE ILLIQUIDITY; PENNY STOCK RESTRICTIONS. Shares of our common stock are quoted and traded from time to time on the OTC Bulletin Board and in the so-called "Pink Sheets," but the quotations and trading activity are limited and sporadic. As a result, our shareholders may find it difficult to obtain accurate quotations concerning the market price of their shares. Our shareholders also may experience more difficulty in attempting to sell their shares than if the shares were listed on a national stock exchange or quoted on the NASDAQ Stock Market. Also, our common shares are classified as a "penny stock" because they are not traded on a national stock exchange or on the NASDAQ Stock Market and the market price is less than $5 per share. Rules of the Securities and Exchange Commission impose additional sales practice requirements on broker-dealers that recommend the purchase or sale of penny stocks to persons other than those who qualify as an "established customer" or an "accredited investor." Among other things, a broker-dealer must make a determination that investments in penny stocks are suitable for the customer and must make special disclosures to the customer concerning the risks of penny stocks. Application of the Penny Stock Rules to our common shares could adversely affect the market liquidity of the shares, which in turn may adversely affect the ability of shareholders to sell their shares.
    
    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
    
    THREE AND SIX MONTHS ENDED OCTOBER 31, 2006 AND 2005
    
    SALES
    
    Our revenues from operations for the three and six months ended October 31, 2006 were $197,779 and $698,758, respectively. Our revenues from operations for the three and six months ended October 31, 2005 were $0 and $0. The increase in our revenues was due to our sales of Cinnergen and our distribution agreement with Nutralab.
    
    RESEARCH AND DEVELOPMENT
    
    During the three and six months ended October 31, 2006, we incurred research and development expenses of $43,614 and $56,819, respectively. Most of these expenses were from our two wholly-owned subsidiaries, Knock-Out Technologies, Inc. and MedElite, Inc. For the three and six months ended October 31, 2006, Knock-Out Technologies incurred research and development expenses of $3,847 and $7,291, respectively while MedElite, Inc. incurred research and development expenses of $19,767 and $29,528, respectively. During the three and six months ended October 31, 2005, the Company incurred research and development expenses of $43,438 and $43,438, respectively.
    
    SELLING, GENERAL AND ADMINISTRATIVE EXPENSES
    
    A summary of our Selling, General and Administrative costs is as follows:
    
    During the three and six months ended October 31, 2006, the Company incurred sales and marketing expense of $78,955 and $986,269, respectively, compared to sales and marketing expense of $60,800 and $60,800 during the three and six months ended October 31, 2005. The increase in sales and marketing expense is primarily due to payments made pursuant to our distribution agreement with Nutralab.
    
    Cash and stock compensation were paid for consulting fees, for outside directors, legal advisors and marketing consultants. The Company issued 2,000,000 shares of common stock for expenses of $500,000. The Company also issued 1,500,000 shares of common stock to settle a lawsuit. Th
13. [verwijderd] 11 januari 2007 12:11

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    eFoodSafety.com, Inc.'s Cinnergen, a Featured Product at Kroger Supermarkets
    Monday December 18, 10:05 am ET
    Company Expands Retail Distribution Network into One of the Nations Largest Grocery Retailers
    
    SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that the Company's Cinnergen(TM) product, a once-a-day formula made from 15 whole foods that contain no fats, carbohydrates, sugar, or calories, that is designed to regulate blood sugar is now featured at Kroger Supermarkets (http://www.thekrogerco.com).
    
    ADVERTISEMENT
    The Kroger Co. (NYSE:KR - News), headquartered in Cincinnati, Ohio, is one of the nation's largest grocery retailers, with fiscal 2005 sales of $60.6 billion. Kroger operates in 31 states under two dozen names, including Kroger, Ralphs, Fred Meyer, King Soopers, Food 4 Less, Dillon, Smith's, City Market, QFC and Fry's. At the end of fiscal 2005, Kroger operated 2,507 supermarkets and multi-department stores, 791 convenience stores and 428 fine jewelry stores. Kroger Manufacturing has 42 food processing plants that support its retail grocery operations.
    
    Although considered "neighborhood stores" - in terms of size, shopping experience, and travel time - they are large enough to offer the high-margin specialty departments that customers desire. Specialty departments include: whole health sections, pharmacies, pet centers and world-class perishables, such as fresh seafood and organic produce.
    
    Patricia Gruden, President and CEO of eFoodSafety.com, Inc. stated, "The addition of The Kroger Co., one of the nation's largest grocery retailers, to our growing chain of retailers featuring Cinnergen(TM) is something we're extremely proud of. Not only does it substantiate the viability of the brand but it also opens up a significant sales channel. Cinnergen(TM) has traditionally been featured primarily in health food and nutritional stores such as GNC and The Vitamin Shoppe. However, The Kroger Co, a supermarket conglomerate with a large geographic footprint, is an immense sales channel we have yet to attempt to capitalize on. We're looking forward to working with Kroger's to further build the Cinnergen brand and increase product sell-through."
    
    About eFoodSafety.com, Inc.
    
    eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The company is also owner of Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
    
    Please visit the Company's website at: www.efoodsafety.com.
14. [verwijderd] 11 januari 2007 12:11

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Income Statement Get Income Statement for:
    View: Annual Data | Quarterly Data All numbers in thousands
    PERIOD ENDING 31-Oct-06 31-Jul-06 30-Apr-06 31-Jan-06
    Total Revenue 198 501 421 116
    Cost of Revenue - - - -
    Gross Profit 198 501 421 116
    Operating Expenses
    Research Development 44 13 57 18
    Selling General and Administrative 773 1,592 6,035 486
    Non Recurring 11 390 (2,019) 2,019
    Others - - - -
    
    Total Operating Expenses - - - -
    Operating Income or Loss (630) (1,495) (3,652) (2,407)
    Income from Continuing Operations
    Total Other Income/Expenses Net 8 8 (1,699) 1,699
    Earnings Before Interest And Taxes (622) (1,487) (5,351) (708)
    Interest Expense 8 8 4 21
    Income Before Tax (630) (1,495) (5,356) (728)
    Income Tax Expense - - - -
    Minority Interest - - - -
    
    Net Income From Continuing Ops (630) (1,495) (5,356) (728)
    Non-recurring Events
    Discontinued Operations - - - -
    Extraordinary Items - - - -
    Effect Of Accounting Changes - - - -
    Other Items - - - -
    Net Income (630) (1,495) (5,356) (728)
    Preferred Stock And Other Adjustments - - - -
    Net Income Applicable To Common Shares ($630) ($1,495) ($5,356) ($728)
    
    
15. [verwijderd] 11 januari 2007 12:12

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    eFoodSafety.com, Inc. Subsidiary Knock-Out Technologies, Ltd. Developing Joint Licensing Agreement with United States Department of Agriculture (USDA) for Patent-Pending OraPhyte Product
    Wednesday January 10, 4:15 pm ET
    OraPhyte is Designed to Combat Plant-Parasitic Nematodes That Cause an Annual Estimated Crop Loss of $100 Billion Globally
    
    SCOTTSDALE, Ariz.--(BUSINESS WIRE)--eFoodSafety.com, Inc. (OTCBB:EFSF - News), a Company dedicated to improving health conditions around the world through innovative products and technologies, today announced that its wholly-owned subsidiary, Knock-Out Technologies, Ltd. and the United States Department of Agriculture (USDA) are working on a licensing agreement on the company's patent-pending parasitic product, OraPhyte, a product derived from the Company's patented Citroxin product that kills and controls plant-parasitic Nematodes. The agreement will be based on a new use for OraPhyte specifically developed for the control of plant Nematodes.
    
    ADVERTISEMENT
    The USDA provides leadership on food, agriculture, natural resources, rural development and related issues based on sound public policy, the best available science, and efficient management. The key to the testing by the USDA, which commenced in June 2005, is that the OraPhyte product has been found to be an effective alternative to the existing method used, methyl-bromide, which has been found to present various toxic environmental issues.
    
    The significance of this licensing agreement, expected to be completed within the next 60-120 days, is that Knock-Out Technologies will be able to release all of the USDA's research data as well as being able to leverage its endorsement in marketing the product.
    
    Plant-parasitic Nematodes are microscopic worms that cause an estimated crop loss of $100 billion globally. In the U.S., farmers face over $10 billion in annual losses due to Nematodes, without an acceptable solution currently available. OraPhyte has been designed to address this costly issue.
    
    Robert Bowker, President of Knock-Out Technologies, Ltd., stated, "Our environmentally-safe and effective product, OraPhyte, is a novel and potentially groundbreaking solution to this $100 billion problem. The fact that the USDA has tested our product and is finalizing a licensing agreement with us speaks volumes about the potential of OraPhyte as well as the possible financial impact this product could have on the multi-billion dollar Nematode market."
    
    Patricia Gruden, President and CEO of eFoodSafety.com, Inc., added, "We fully intend to continue to communicate with our shareholders and potential investors regarding the finalization of the Licensing Agreement as well as other material developments regarding OraPhyte."
    
    About eFoodSafety.com, Inc.
    
    eFoodSafety.com, Inc. is dedicated to improving health conditions around the world through its innovative technologies. The company's Knock-Out Technologies, Ltd. subsidiary has developed an environmentally safe sporicidal product formulated entirely of food-grade components that eradicates anthrax and a germicidal product, Citroxin (formerly named Big Six Plus) - EPA Reg. No. 82723-1 that kills six major bacteria: E-coli, Listeria, Pseudomonas, Salmonella, Staphylococcus, and Streptococcus, Avian Influenza, and Black Mold. The sporicidal product has completed its final efficacy laboratory study requisite for EPA registration. In the study, it eradicated both Clostridium Sporogenes and Bacillus Subtilis with 100% efficacy on both hard and porous surfaces. The company's MedElite, Inc. subsidiary distributes clinically proven products to physicians who then prescribe the products for their patients. It recently became the owner of the Talsyn(TM)-CI/bid Scar Cream, that has been clinically proven to facilitate and improve the appearance, redness and strength of scars (www.talsyn.com), as well as seven (7) other products in the Talsyn(TM) line. The company is also owner of Cinnergen(TM), a non-prescription liquid whole food nutritional supplement that promotes healthy glucose metabolism (www.cinnergen.com), and Trimmendous(TM), a weight loss formula focusing on the body's 24-hour metabolic processes. The company has entered into a joint venture agreement with CK41 Direct, Inc. to launch the PurEffect(TM) anti-acne skin care system.
    
    Please visit the Company's website at: www.efoodsafety.com.
    
    Safe Harbor Forward-Looking Statements
16. [verwijderd] 11 januari 2007 12:20

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Influenza A, vogelgriep, ziekte van Lhyme, Nematoden/gewassen, anthrax...
    Licensing agreement met US Department of Agriculture...
    
    Houd dit kleine stuk vreten in de gaten, want als de gekte erop komt...
    
    Er staan nogal wat shorts uit, wat je ook merkt bij (goede) berichten. In de buurt van de .19 wordt er hard naar beneden gebeukt.
    Het nieuws van gisteren zou wel eens een lont in het kruitvaatje kunnen zijn, gezien de status van de partner.
    Voor dit jaar staat tevens de marktintroductie van hun anti-acne creme op het programma, in samenwerking met een soort tell-sell achtige organisatie (eentje met een paar honderd miljoen jaarlijkse omzet, en een nu nog onbekende celebrity (Tom Berenger lijkt mij persoonlijk wel geschikt, maar of daar nog wat van te maken is...).
    Omzet o.b.v. cinnergen neemt redelijk toe, en het produkt wordt op steeds meer plaatsen verkocht. Voldoende kasmiddelen om het ieg dit (boek)jaar uit te zingen.
    Uitstaande aandelen na gewonnen rechtszaak tegen ex-directeur onlangs met 20-25% (zie hierboven) ingekrompen, nu volgens mij zo'n 140 miljoen.
    
    Laatste bericht lijkt een eerste echte bevestiging van de acceptatie van hun produkten/credibility van het bedrijfje.
    Website(s) vind ik matig que professionele uitstraling.
    
17. [verwijderd] 11 januari 2007 12:23

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    eFoodSafety.com, Inc. (EFSF) SqueezeTrigger Price is $0.32 -- Approximately 17.2 Million Shares Shorted Since January 2005 According to Buyins.net Research Report
    Monday November 27, 9:30 am ET
    The First of Several Short Squeezes is Expected to Begin When Shares of EFSF Close above $0.20
    
    Vandaag kans op squeeze.
    
    Overigens lijken de uitgaven voor R&D wel belachelijk laag:)
    (During the three and six months ended October 31, 2006, we incurred research and development expenses of $43,614 and $56,819, respectively. Most of these expenses were from our two wholly-owned subsidiaries, Knock-Out Technologies, Inc. and MedElite, Inc. For the three and six months ended October 31, 2006, Knock-Out Technologies incurred research and development expenses of $3,847 and $7,291, respectively while MedElite, Inc. incurred research and development expenses of $19,767 and $29,528, respectively. During the three and six months ended October 31, 2005, the Company incurred research and development expenses of $43,438 and $43,438, respectively.)
18. [verwijderd] 11 januari 2007 12:30

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Enige actieve message board voor efsf dat ik kan vinden is op ragingbull.com.
    Informatieve waarde vrijwel nihil.
19. [verwijderd] 11 januari 2007 12:48

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    From OTC Journal:
    
    Have you ever heard the phrase "The Awesome Burden of Permanent Potential". That phrase describes eFoodSafety (OTC BB: EFSF). Permanent potential is going to convert to tangible results throughout the course of 2007.
    
    EFSF has traded to much higher levels in the past as investors anticipated product developments would lead to commercial success. In March of last year the stock traded up as high as $.60- more than three times the current level. I believe it's going back there, and this time as a result of strong sales of products which are hitting the store shelves and commercial airwaves today.
    
    EFSF describes itself as "dedicated to improving health conditions around the world through its innovative technologies". This company has been developing some very exciting items over the last several years, and is positioned to see sales skyrocket in 2007 with commercial introductions.
    
    If they hit on just one of the three products I am going to show you today, sales could jump from about $1 million annually to $30 to $50 million plus annually. If so, we are looking at a potential 5 to 10 bagger from current levels: a $1 stock plus.
    
    Here's a quick review of their breakthrough products for 2007:
    
    Cinnergen: The Carb Buster
    
    The product you see here is currently on the shelves in about 6,000 retail outlets throughout the US including Kroger's, King Soopers, GNC, Vitamin World, and many others. By the end of March, that number should go up to 10,600 retail outlets- including some much larger household names. You can also see this product advertised in short commercials on CNN, The Price Is Right (syndicated), and a few other national TV venues.
    
    It retails for about $30 for a 32 oz bottle, and $15 for a 16 oz bottle.
    
    You simply drink a 1 oz cap full every morning when you wake up, and the product helps you body metabolize sugars and carbohydrates. In short, it helps convert sugar into energy instead of fat. It helps you lose weight.
    
    A clinical study will be published before the end of January confirming it works. The ingredients, which include cinnamon extract and blueberry leaf extract, have been proven independently to help your body metabolize sugar. EFSF is the first to combine them into one, easy to take formula.
    
    There are numerous testimonials from diabetics on their web site confirming the product does indeed help control blood sugar levels. If you want to read the testimonials, here's a short cut: Click Here.
    
    Here are the numbers: if every retail outlet averages four sales per month of the 32 oz bottle, it equates to about $700k per month in revenues, or $8.4 million in annual sales. This about 8x last year's revenue figures, and just the beginning. There are some retailers looking to add the product once the study is published who would sell in substantially larger quantities relative to their size.
    
    Look for additional, high profile retail names to start carrying Cinnergen. There could be catalytic announcements which would send the stock surging. Numbers and advertising are going to increase from here.
    
    Product #2: PurEffect- Taking on ProActive
    
    Have you ever heard of ProActiv? For about 8 years I saw a monthly charge on my credit card bill for $30 to pay for my teenager daughter's monthly shipment.
    
    ProActiv is endorsed by celebrities like Jessica Simpson, Vanessa Williams, Lindsey Lohan, Kelly Clarkson, and my personal favorite, Alicia Keys. The company sells $650 million worth of product every year, and is widely considered the 1200 lb gorilla in products used to treat acne, a teenagers' worst nightmare.
    
    Enter PurEffect. EFSF has developed a product it believes is better than ProActiv, and it will be hitting the market via infomercial and celebrity endorsement.
    
    Here's the best part of the arrangement for EFSF shareholders. The entire infomercial campaign will be organized, managed, produced, and funded by CK41 Direct- a private company in the infomercial marketing business. CK41 will cover all expenses and split the profits 50/50 with EFSF.
    
    CK41 Direct is run by a bunch of ex Gunthy-Renker folks who's resumes include "Ab Away Pro," "Body by Jake" fitness products, and "Rapid White" tooth whitening system. Other successes include the "Ab Sculptor" with more than $100 million in sales and the "Ab Doer" with sales in excess of $350 million.
    
    Here's a quote: "CK41 anticipates estimated revenue at more than $100 million in gross sales in the first full year of the infomercial's national roll-out in the U.S. market alone," stated Christine McDonald, president and CEO of CK41 Direct.
    
    The infomercial is in production right now, and expected to start airing before the end of Q1 '07. There will be celebrity endorsements, and in a few weeks the names will be disclosed.
    
    OraPhyte: Attacking the $100 Billion Nematode Problem
    
    Pictured here are some slimy, microscopic critters known as NEMATODES. This little guys are responsible for about $100 billion in crop damage worldwide every year. There are over 20,000 different species of these things, and 15,000 of them are parasitic.
    
    Also known as and confused with Round Worms, nematodes get into and eat plant roots. They do $10 billion in crop damage every year in the US alone, and there is little or nothing the agricultural industry can do about them in an environmentally safe manner.
    
    EFSF has developed a product known as OraPhyte which kills and controls plant-parasitic nematodes. Once available, OraPhyte will be about the only product available that can deal with the crop damage.
    
    So, where are we in terms of a commercial roll out of OraPhyte? Today, just after the close, we learned that OraPhyte has been in testing with the US Department of Agriculture since June of 2005. The USDA is expected to release its findings in the next 60 days, and enter into a licensing agreement with EFSF which will include an endorsement of the efficacy and safety of the product.
    
    Currently, nematodes are fought using methyl-bromide, a substance found to be toxic and environmentally unsafe. The Montreal Protocol, an international treaty designed to identify and disrupt the use of ozone depleting substances, has placed methyl-bromide on its "phase out" list, meaning stop using it!
    
    The Bush administration, which refuses to accept Global Warming as a reality, has allowed its continued use. Methyl-Bromide is likely to be taken out of circulation in the US soon, and other countries internationally are screaming for an environmentally safe product now.
    
    Conclusion: Almost No Down Side and Big Upside
    
    When I first stared looking at EFSF I felt it had the characteristics required for a profitable microcap trade. Here are some pending events that could send this stock rocketing up the charts:
    
    The clinical study on Cinnergen will be published. It will lead to much greater sales and an expanded network of retail outlets, including some major household names.
    PurEffect will be endorsed by teen idol celebrities. Those celebrities will be disclosed to the public, and a launch schedule for the infomercial will be disclosed as well.
    The USDA will publish its findings on OraPhyte, finalize its licensing agreement with EFSF, and marketing of the product will begin with the best endorsement available on the planet.
    As if that weren't enough possibilities, EFSF has several other products nearing commercial availability. A natural cholesterol fighting product will b
20. [verwijderd] 11 januari 2007 16:07

    auteur info

    •    [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    •    Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Flinke actie.

    Bijlage: